Mild Cognitive Impairment and Mild Dementia: The Role of Ginkgo biloba (EGb 761®)
Autor: | Vincenzo Solfrizzi, Carolina Muscoli, Guglielmo Zilio, Paolo Maria Rossini, Sara Ilari, Stefania Proietti, Valentina Malafoglia, Patrizia Russo, Federica Marcolongo, Carlo Tomino, Giovanni Scapagnini |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
Combination therapy Pharmaceutical Science lcsh:Medicine lcsh:RS1-441 Review law.invention lcsh:Pharmacy and materia medica 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Ginkgo biloba (Egb761®) Internal medicine Drug Discovery mental disorders medicine Dementia Cognitive decline Mild cognitive impairment (MCI) Tebonin 030304 developmental biology 0303 health sciences biology Ginkgo biloba business.industry anti-dementia drugs lcsh:R Cognition medicine.disease biology.organism_classification mild cognitive impairment (MCI) mild dementia Alzheimer’s disease randomized controlled trials Molecular Medicine Caregiver stress business 030217 neurology & neurosurgery |
Zdroj: | Pharmaceuticals, Vol 14, Iss 305, p 305 (2021) Pharmaceuticals |
Popis: | Mild cognitive impairment (MCI) and dementia are clinically prevalent in the elderly. There is a high risk of cognitive decline in patients diagnosed with MCI or dementia. This review describes the effectiveness of Ginkgo biloba leaf special extract EGb 761® for the treatment of dementia syndromes and EGb 761® combination therapy with other medications for symptomatic dementia. This drug has shown convincing results, improving cognitive function, neuropsychiatric symptoms and consequent reduction of caregiver stress and maintenance of autonomy in patients with age-related cognitive decline, MCI and mild to moderate dementia. Currently, there is little evidence to support the combination therapy with anti-dementia drugs and, therefore, more evidence is needed to evaluate the role of EGb 761® in mixed therapy. |
Databáze: | OpenAIRE |
Externí odkaz: |